HIV & Aging Clinical Recommendations

Chapter 3

When to Initiate Antiretroviral Therapy in HIV and Aging

For older HIV-infected patients, antiretroviral therapy is recommended for all, regardless of CD4 cell count.

  • Antiretroviral therapy is extremely important for older HIV-infected patients as these individuals have a greater risk of developing serious non-AIDS complications.
  • Antiretroviral therapy should be initiated as early as possible in older patients due to the frequent blunted immune response and relatively poor CD4 cell increases in response to antiretroviral therapy.
  • Clinicians should not withhold therapy in older patients due to concerns for poor virologic responses to therapy as available data suggest older patients have high virologic response rates.
  • Older patients on antiretroviral therapy should receive close monitoring for adverse drug effects related to antiretroviral therapy.

Multiple cohort studies involving untreated HIV-infected persons have established that older persons have a more rapid progression to AIDS and shortened survival when compared with younger persons (Balslev 1997; Phillips 2008a; Rezza 1998; Egger 2002). For HIV-infected persons older than 50, limited data exist from randomized, controlled antiretroviral therapy clinical trials, as most randomized therapy trials have excluded persons older than 50 or 60. A retrospective analysis of 253 patients 50 years of age or older found antiretroviral therapy substantially improved survival rates (Perez 2003). Several large retrospective studies have clearly shown delayed and diminished CD4 cell recovery after starting antiretroviral therapy in older HIV-infected patients when compared with younger age groups (Khanna 2008; Silverberg 2007; Althoff 2010a; Sabin 2008). Studies have shown conflicting results with respect to virologic responses in older versus younger (Silverberg 2012; Paredes 2000; Manfredi 1999; Lampe 2006), with the most comprehensive study showing high virologic response rates (Horberg 2015) and no significant difference in virologic responses based in older versus younger adults (Althoff 2010a).

The major antiretroviral therapy guidelines that most influences clinical practice in the United States—the Department of Health and Human Services (DHHS) Panel guidelines (DHHS 2016a)—recommends initiating antiretroviral therapy in all persons infected with HIV. The recommendation to use antiretroviral therapy in all HIV-infected persons is based on reducing the risk of disease progression and decreasing the risk of HIV transmission. Data from several large cohort studies have strongly suggested a survival advantage with initiation of antiretroviral therapy earlier in the course of HIV disease (Kitahata 2009; Sterne 2009). In addition, growing evidence suggests that uncontrolled HIV infection produces a “chronic inflammatory state” associated with an increased risk of developing cardiovascular disease (Phillips 1991) and non-AIDS malignancies (Bruyand 2009), and CD4 counts below 500 are associated with higher cardiovascular risk (Lichtenstein 2010), and risk for non-AIDS malignancies (Guiguet 2009). Further, in a large cohort study, investigators reported 10-year mortality in persons 45 to 65 years of age was lower when antiretroviral therapy was initiated at a CD4 threshold of 500 cells/mm3 than delaying to a threshold of 350 cells/mm3 (Edwards 2015). The rationale for recommending antiretroviral therapy for the prevention of HIV transmission is based on several recent studies, most notably the landmark HPTN 052 trial that showed a greater than 95% reduction in HIV transmission in HIV serodiscordant couples when the HIV-infected partner received antiretroviral therapy (Cohen 2011).

The January 2016 DHHS Antiretroviral Therapy guidelines specifically addressed the use of antiretroviral therapy for persons 50 and older, recommending initiating antiretroviral therapy in all persons older than 50 years of age regardless of CD4 cell count, primarily because, when compared with younger patients, these older HIV-infected individuals have increased risk for non-AIDS related complications and they have diminished CD4 cell count recovery in response to antiretroviral therapy (DHHS 2016a). Further, the DHHS guidelines emphasized that older individuals potentially have increased risk for HIV transmission or acquisition, for several reasons, including (1) alterations reduced mucosal and immunologic defenses may occur with post-menopausal atrophic vaginitis, (2) older individuals have less incentive to use of condoms given the lack of need for pregnancy prevention, and (3) persons older than 50 have lower frequency of HIV screening given their perceived low risk for HIV infection (Adekeye 2012).

The use of antiretroviral therapy in older HIV-infected patients presents several challenges, predominantly due to the increased prevalence of non-HIV-related comorbid medical conditions, such as hyperlipidemia, hypertension, diabetes, and coronary artery disease (Skiest 1996). In addition, older patients may have age-related changes in body composition that can alter medication volume of distribution and influence drug pharmacokinetics. Compared with younger patients, older patients are more likely to be taking multiple medications not related to HIV and thus increasing the likelihood for drug-drug interactions. Further, several studies have shown older HIV- infected patients have increased risk for developing drug-related toxicity, including hyperglycemia, elevated creatinine, and unfavorable alterations in lipid profile (Silverberg 2007).

Updated on: 
Monday, June 5, 2017
Updated by: 
David Spach, MD


Purpose of this Program: The AAHIVM, ACRIA and AGS (collectively, the “Sponsors,” “we” or “us”) are sponsors of this Website and through it seek to address the unique needs and challenges that older adults of diverse populations living with HIV face as they age. However, the information in this Website is not meant to supplant the advice provided in a doctor-patient relationship.

General Disclaimer: is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.



Phone: 202-659-0699
Fax: 202-659-0976


AAHIVM National Office
1627 Eye St NW Suite 835
Washington, D.C. 20006


The American Academy of HIV Medicine is a professional organization that supports the HIV practitioner and promotes accessible, quality care for all Americans living with HIV disease. Our membership of HIV practitioners and credentialed HIV Specialists™, HIV Experts™, and HIV Pharmacists™ provide direct care to the majority of HIV patients in the US.